Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer" [Eur J Cancer 189 (2023) 112919].

European journal of cancer (Oxford, England : 1990)·2025
Same author

Differential expression of the MYC-Notch axis drives divergent responses to the front-line therapy in central and peripheral extensive-stage small-cell lung cancer.

MedComm·2025
Same author

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer.

Cancer immunology, immunotherapy : CII·2025
Same author

Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma.

Cancer research and treatment·2025
Same author

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study.

Journal of hematology & oncology·2024
Same author

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2024

Related Experiment Video

Updated: Mar 22, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

PD-L1 Expression in Lung Cancer.

Hui Yu1, Theresa A Boyle2, Caicun Zhou3

  • 1Department of Medicine/Medical Oncology, University of Colorado Cancer Center, University of Colorado, Denver, Colorado.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 28, 2016
PubMed
Summary

Programmed death ligand 1 (PD-L1) immunotherapy improves lung cancer survival. Harmonizing PD-L1 testing is crucial for accurate patient selection and effective treatment.

Keywords:
BiomarkerImmunotherapyLung cancerPD-L1

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.5K

Related Experiment Videos

Last Updated: Mar 22, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.5K

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Immunotherapies targeting programmed death ligand 1 (PD-L1) and programmed death 1 (PD-1) have shown efficacy in advanced lung cancer.
  • PD-L1 protein expression is a key biomarker for predicting response to these immunotherapies.
  • Current challenges exist in standardizing PD-L1 detection methods across different clinical trials.

Purpose of the Study:

  • To review the historical use of PD-L1 as a biomarker in immunotherapy.
  • To identify and discuss the complexities in PD-L1 detection and interpretation.
  • To highlight the need for harmonization for optimal patient care.

Main Methods:

  • Literature review of PD-L1 biomarker studies in lung cancer immunotherapy.
  • Analysis of historical data from clinical trials using different PD-L1 assays.
  • Synthesis of challenges in PD-L1 testing and interpretation.

Main Results:

  • PD-L1 expression has been established as a predictive biomarker for immunotherapy response.
  • Variability in immunohistochemistry platforms, antibodies, scoring systems, and cut-offs complicates PD-L1 interpretation.
  • Lack of standardization hinders consistent application of PD-L1 testing.

Conclusions:

  • Standardization of PD-L1 detection and interpretation is essential for reliable patient stratification.
  • Addressing the challenges in PD-L1 assay harmonization is critical for improving patient outcomes with immunotherapy.
  • Further research and consensus are needed to establish unified guidelines for PD-L1 biomarker use.